Oricell Therapeutics Holdings Limited, a clinical-stage biotechnology company developing next-generation cell therapies for oncology and immunology, announced on Thursday the cumulative closing of a pre-IPO financing round in excess of USD110m.

The round was co-led by Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners, and a leading global healthcare fund. The syndicate included an international sovereign wealth fund, E-Town Capital, Luxin Venture Capital, NGS Super, Elikon Investment, and Talon Capital.

The company intends to use the proceeds to accelerate its global expansion and clinical development, while strengthening its technological capabilities and paving the way to capital market milestones.

OriCell's lead asset, Ori-C101, is a GPC3-targeted autologous CAR-T therapy for advanced hepatocellular carcinoma (HCC). Having successfully navigated investigator-initiated trials (IIT) and a registrational Phase 1 study, the programme is now preparing for pivotal trials.

Beyond its lead asset, Oricell is advancing a diverse portfolio of next-generation modalities, including secreted, rapid-production, and in vivo CAR-T programmes.